Lisata Therapeutics
LSTA
22 hedge funds and large institutions have $2.03M invested in Lisata Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
39% more capital invested
Capital invested by funds: $1.46M → $2.03M (+$572K)
5% more funds holding
Funds holding: 21 → 22 (+1)
0.74% more ownership
Funds ownership: 8.41% → 9.15% (+0.74%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$79.2K |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$61.1K |
| 3 |
Morgan Stanley
New York
|
+$4.7K |
| 4 |
Renaissance Technologies
New York
|
+$3.52K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$10.5K |
| 2 |
BlackRock
New York
|
-$1.31K |
| 3 |
FCMT
Founders Capital Management (Texas)
Houston,
Texas
|
-$782 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$52 |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$21 |
LSTA Hedge Fund Activity: Q4 2023 in Review
22 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q4 2023, worth a combined $2.03M — up 39% from $1.46M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new LSTA positions and 1 closed out — a net gain of 1 holder — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $79.2K. The largest seller was Citadel Advisors, cutting an estimated $10.5K.
- 22 institutional investors held Lisata Therapeutics (LSTA) as of Q4 2023, up from 21 in Q3 2023.
- Funds reported $2.03M of Lisata Therapeutics stock for Q4 2023, up 39% quarter-over-quarter.
- 2 funds opened new Lisata Therapeutics positions in Q4 2023 and 1 closed out, a net change of +1 holder.
- The largest Lisata Therapeutics buyer in Q4 2023 was Susquehanna International Group, an estimated $79.2K added.
- The largest Lisata Therapeutics seller in Q4 2023 was Citadel Advisors, an estimated $10.5K sold.
Based on aggregated 13F filings for Q4 2023.